-
1
-
-
0033524482
-
A two-step, two-signal model for the primary activation of precursor helper T cells
-
Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A. 1999;96(1): 185-190.
-
(1999)
Proc Natl Acad Sci U S A
, vol.96
, Issue.1
, pp. 185-190
-
-
Bretscher, P.A.1
-
2
-
-
10844292763
-
Immunosuppressive drugs for kidney transplantation
-
Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715-2729.
-
(2004)
N Engl J Med
, vol.351
, Issue.26
, pp. 2715-2729
-
-
Halloran, P.F.1
-
3
-
-
65349189555
-
Costimulatory pathways in transplantation: Challenges and new developments
-
Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev. 2009;229(1):271-293.
-
(2009)
Immunol Rev
, vol.229
, Issue.1
, pp. 271-293
-
-
Li, X.C.1
Rothstein, D.M.2
Sayegh, M.H.3
-
5
-
-
0035202768
-
The immunological synapse and CD28-CD80 interactions
-
Bromley SK, Iaboni A, Davis SJ, et al. The immunological synapse and CD28-CD80 interactions. Nat Immunol. 2001;2(12):1159-1166.
-
(2001)
Nat Immunol
, vol.2
, Issue.12
, pp. 1159-1166
-
-
Bromley, S.K.1
Iaboni, A.2
Davis, S.J.3
-
7
-
-
0031727486
-
The role of B7 costimulation in activation and differentiation of CD4+ and CD8+ T cells
-
McAdam AJ, Schweitzer AN, Sharpe AH. The role of B7 costimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev. 1998;165:231-247.
-
(1998)
Immunol Rev
, vol.165
, pp. 231-247
-
-
McAdam, A.J.1
Schweitzer, A.N.2
Sharpe, A.H.3
-
8
-
-
33748428203
-
T-cell costimulation - biology, therapeutic potential, and challenges
-
Sharpe AH, Abbas AK. T-cell costimulation - biology, therapeutic potential, and challenges. N Engl J Med. 2006;355(10):973-975.
-
(2006)
N Engl J Med
, vol.355
, Issue.10
, pp. 973-975
-
-
Sharpe, A.H.1
Abbas, A.K.2
-
9
-
-
0029914089
-
Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions
-
Greene JL, Leytze GM, Emswiler J, et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J Biol Chem. 1996;271(43):26762-26771.
-
(1996)
J Biol Chem
, vol.271
, Issue.43
, pp. 26762-26771
-
-
Greene, J.L.1
Leytze, G.M.2
Emswiler, J.3
-
10
-
-
0035059417
-
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation
-
Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225-252.
-
(2001)
Annu Rev Immunol
, vol.19
, pp. 225-252
-
-
Salomon, B.1
Bluestone, J.A.2
-
11
-
-
0028484545
-
CTLA-4 can function as a negative regulator of T cell activation
-
Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1(5):405-413.
-
(1994)
Immunity
, vol.1
, Issue.5
, pp. 405-413
-
-
Walunas, T.L.1
Lenschow, D.J.2
Bakker, C.Y.3
-
12
-
-
0030744132
-
Functions of CD40 on B cells, dendritic cells and other cells
-
van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997;9(3):330-337.
-
(1997)
Curr Opin Immunol
, vol.9
, Issue.3
, pp. 330-337
-
-
van Kooten, C.1
Banchereau, J.2
-
13
-
-
0031944607
-
CD40 and CD154 in cell-mediated immunity
-
Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111-135.
-
(1998)
Annu Rev Immunol
, vol.16
, pp. 111-135
-
-
Grewal, I.S.1
Flavell, R.A.2
-
14
-
-
0034665321
-
Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis
-
Shimizu K, Schönbeck U, Mach F, Libby P, Mitchell RN. Host CD40 ligand defciency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol. 2000;165(6):3506-3518.
-
(2000)
J Immunol
, vol.165
, Issue.6
, pp. 3506-3518
-
-
Shimizu, K.1
Schönbeck, U.2
Mach, F.3
Libby, P.4
Mitchell, R.N.5
-
15
-
-
0033965079
-
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
-
Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6(2):114.
-
(2000)
Nat Med
, vol.6
, Issue.2
, pp. 114
-
-
Kawai, T.1
Andrews, D.2
Colvin, R.B.3
Sachs, D.H.4
Cosimi, A.B.5
-
16
-
-
65349188127
-
Translating costimulation blockade to the clinic: Lessons learned from three pathways
-
Ford ML, Larsen C P. Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev. 2009;229(1): 294-306.
-
(2009)
Immunol Rev
, vol.229
, Issue.1
, pp. 294-306
-
-
Ford, M.L.1
Larsen, C.P.2
-
18
-
-
12644262358
-
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
-
Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA. 1997;94(16):8789-8794.
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, Issue.16
, pp. 8789-8794
-
-
Kirk, A.D.1
Harlan, D.M.2
Armstrong, N.N.3
-
20
-
-
15844404353
-
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
-
Larsen C P, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381(6581):434-438.
-
(1996)
Nature
, vol.381
, Issue.6581
, pp. 434-438
-
-
Larsen, C.P.1
Elwood, E.T.2
Alexander, D.Z.3
-
21
-
-
20044386299
-
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties
-
Larsen C P, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5(3): 443-453.
-
(2005)
Am J Transplant
, vol.5
, Issue.3
, pp. 443-453
-
-
Larsen, C.P.1
Pearson, T.C.2
Adams, A.B.3
-
22
-
-
67649122193
-
Costimulatory blockade with belatacept in clinical and experimental transplantation - a review
-
Emamaullee J, Toso C, Merani S, Shapiro AM. Costimulatory blockade with belatacept in clinical and experimental transplantation - a review. Expert Opin Biol Ther. 2009;9(6):789-796.
-
(2009)
Expert Opin Biol Ther
, vol.9
, Issue.6
, pp. 789-796
-
-
Emamaullee, J.1
Toso, C.2
Merani, S.3
Shapiro, A.M.4
-
23
-
-
0035180065
-
Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance
-
Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18-32.
-
(2001)
Immunol Rev
, vol.182
, pp. 18-32
-
-
Sakaguchi, S.1
Sakaguchi, N.2
Shimizu, J.3
-
24
-
-
51849108540
-
The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation
-
Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008;8(10):2086-2096.
-
(2008)
Am J Transplant
, vol.8
, Issue.10
, pp. 2086-2096
-
-
Bluestone, J.A.1
Liu, W.2
Yabu, J.M.3
-
25
-
-
84864127871
-
Time-varying belata-cept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients
-
Zhou Z, Shen J, Hong Y, Kaul S, Pfster M, Roy A. Time-varying belata-cept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther. 2012;92(2):251-257.
-
(2012)
Clin Pharmacol Ther
, vol.92
, Issue.2
, pp. 251-257
-
-
Zhou, Z.1
Shen, J.2
Hong, Y.3
Kaul, S.4
Pfster, M.5
Roy, A.6
-
26
-
-
23944502334
-
Costimulation blockade with belata-cept in renal transplantation
-
Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belata-cept in renal transplantation. N Engl J Med. 2005;353(8):770-781.
-
(2005)
N Engl J Med
, vol.353
, Issue.8
, pp. 770-781
-
-
Vincenti, F.1
Larsen, C.2
Durrbach, A.3
-
27
-
-
77956528156
-
Five-year safety and efficacy of belatacept in renal transplantation
-
Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010;21(9): 1587-1596.
-
(2010)
J Am Soc Nephrol
, vol.21
, Issue.9
, pp. 1587-1596
-
-
Vincenti, F.1
Blancho, G.2
Durrbach, A.3
-
28
-
-
65549169583
-
Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation
-
Latek R, Fleener C, Lamian V, et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation. 2009;87(6):926-933.
-
(2009)
Transplantation
, vol.87
, Issue.6
, pp. 926-933
-
-
Latek, R.1
Fleener, C.2
Lamian, V.3
-
29
-
-
76949101581
-
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)
-
Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535-546.
-
(2010)
Am J Transplant
, vol.10
, Issue.3
, pp. 535-546
-
-
Vincenti, F.1
Charpentier, B.2
Vanrenterghem, Y.3
-
30
-
-
0344553377
-
Heterologous immunity: An overlooked barrier to tolerance
-
Adams AB, Pearson TC, Larsen C P. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev. 2003;196:147-160.
-
(2003)
Immunol Rev
, vol.196
, pp. 147-160
-
-
Adams, A.B.1
Pearson, T.C.2
Larsen, C.P.3
-
31
-
-
34447646310
-
Programmed death-1 ligand 1 interacts specifcally with the B7-1 costimulatory molecule to inhibit T cell responses
-
Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifcally with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111-122.
-
(2007)
Immunity
, vol.27
, Issue.1
, pp. 111-122
-
-
Butte, M.J.1
Keir, M.E.2
Phamduy, T.B.3
Sharpe, A.H.4
Freeman, G.J.5
-
32
-
-
80054851680
-
Costimulatory pathways in transplantation
-
Pilat N, Sayegh MH, Wekerle T. Costimulatory pathways in transplantation. Semin Immunol. 2011;23(4):293-303.
-
(2011)
Semin Immunol
, vol.23
, Issue.4
, pp. 293-303
-
-
Pilat, N.1
Sayegh, M.H.2
Wekerle, T.3
-
33
-
-
76949090842
-
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)
-
Durrbach A, Prestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10(3):547-557.
-
(2010)
Am J Transplant
, vol.10
, Issue.3
, pp. 547-557
-
-
Durrbach, A.1
Prestana, J.M.2
Pearson, T.3
-
34
-
-
79955544132
-
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)
-
Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011;91(9):976-983.
-
(2011)
Transplantation
, vol.91
, Issue.9
, pp. 976-983
-
-
Vanrenterghem, Y.1
Bresnahan, B.2
Campistol, J.3
-
35
-
-
78650831358
-
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies
-
Larsen C P, Grinyó J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010;90(12):1528-1535.
-
(2010)
Transplantation
, vol.90
, Issue.12
, pp. 1528-1535
-
-
Larsen, C.P.1
Grinyó, J.2
Medina-Pestana, J.3
-
36
-
-
84857190451
-
Three-year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT and BENEFIT-EXT)
-
Abstract 229
-
Florman S, Becker T, Bresnahan B, et al. Three-year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT and BENEFIT-EXT). Am J Transplant. 2011;11 (Suppl S2):28-559 [Abstract 229].
-
(2011)
Am J Transplant
, vol.11
, Issue.SUPPL. S2
, pp. 28-559
-
-
Florman, S.1
Becker, T.2
Bresnahan, B.3
-
37
-
-
84855674077
-
Belatacept: A new biologic and its role in kidney transplantation
-
Su VC, Harrison J, Rogers C, Ensom MH. Belatacept: a new biologic and its role in kidney transplantation. Ann Pharmacother. 2012;46(1): 57-67.
-
(2012)
Ann Pharmacother
, vol.46
, Issue.1
, pp. 57-67
-
-
Su, V.C.1
Harrison, J.2
Rogers, C.3
Ensom, M.H.4
-
38
-
-
79953687090
-
Belatacept: A novel biologic for maintenance immunosuppression after renal transplantation
-
Martin ST, Tichy EM, Gabardi S. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy. 2011;31(4):394-407.
-
(2011)
Pharmacotherapy
, vol.31
, Issue.4
, pp. 394-407
-
-
Martin, S.T.1
Tichy, E.M.2
Gabardi, S.3
-
39
-
-
78650887509
-
Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients
-
Ferguson R, Grinyó J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011;11(1):66-76.
-
(2011)
Am J Transplant
, vol.11
, Issue.1
, pp. 66-76
-
-
Ferguson, R.1
Grinyó, J.2
Vincenti, F.3
-
40
-
-
84863393430
-
Summary of the US FDA approval of belatacept
-
Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J. Summary of the US FDA approval of belatacept. Am J Transplant. 2012;12(3): 554-562.
-
(2012)
Am J Transplant
, vol.12
, Issue.3
, pp. 554-562
-
-
Archdeacon, P.1
Dixon, C.2
Belen, O.3
Albrecht, R.4
Meyer, J.5
-
41
-
-
24644437846
-
Incidence of cancer after immunosuppressive treatment for heart transplantation
-
Ippoliti G, Rinaldi M, Pellegrini C, Viganò M. Incidence of cancer after immunosuppressive treatment for heart transplantation. Crit Rev Oncol Hematol. 2005;56(1):101-113.
-
(2005)
Crit Rev Oncol Hematol
, vol.56
, Issue.1
, pp. 101-113
-
-
Ippoliti, G.1
Rinaldi, M.2
Pellegrini, C.3
Viganò, M.4
-
42
-
-
84872234221
-
-
NULOJIX® (belatacept) [package Insert]. Princeton, NJ: Bristol-Myers Squibb; 2011. Available from, Accessed August 23
-
NULOJIX® (belatacept) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011. Available from: http://packageinserts.bms.com/pi/pi_nulojix.pdf. Accessed August 23, 2012.
-
(2012)
-
-
-
43
-
-
78650818523
-
An integrated safety profile analysis of belatacept in kidney transplant recipients
-
Grinyó J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation. 2010;90(12):1521-1527.
-
(2010)
Transplantation
, vol.90
, Issue.12
, pp. 1521-1527
-
-
Grinyó, J.1
Charpentier, B.2
Pestana, J.M.3
|